Biomea Fusion, Inc. Capital Expenditures
Biomea Fusion, Inc. (BMEA) reported Capital Expenditures of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-03-24
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $82.00K, a 925.00% increase year-over-year.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $362.00K, a 89.26% decline from fiscal 2023.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $3.37M, a 227.18% increase from fiscal 2022.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $1.03M, a 67.52% decline from fiscal 2021.
- Biomea Fusion, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $3.17M, a 6117.65% increase from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $82.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $82.00K derived: sum of 3 quarters · filed 2026-03-24 | $268.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-05 | $82.00K derived: sum of 2 quarters · filed 2026-03-24 | $268.00K derived: sum of 3 quarters · filed 2026-03-24 | $327.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $268.00K derived: sum of 2 quarters · filed 2026-03-24 | $327.00K derived: sum of 3 quarters · filed 2026-03-24 | $362.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $186.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $245.00K derived: sum of 2 quarters · filed 2025-11-04 | $280.00K 10-Q · filed 2025-11-04 | $288.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $94.00K 10-Q · filed 2025-08-05 | $102.00K derived: sum of 3 quarters · filed 2026-03-24 | $141.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-03-31 | $35.00K 10-Q · filed 2025-05-05 | $43.00K derived: sum of 2 quarters · filed 2026-03-24 | $82.00K derived: sum of 3 quarters · filed 2026-03-24 | $499.00K derived: sum of 4 quarters · filed 2026-03-24 |
| 2023-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $47.00K derived: sum of 2 quarters · filed 2026-03-24 | $464.00K derived: sum of 3 quarters · filed 2026-03-24 | $3.37M 10-K · filed 2026-03-24 |
| 2023-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $456.00K derived: sum of 2 quarters · filed 2024-10-29 | $3.36M 10-Q · filed 2024-10-29 | $4.07M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $3.32M 10-Q · filed 2024-07-31 | $4.04M derived: sum of 3 quarters · filed 2025-03-31 | $3.98M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $2.91M 10-Q · filed 2024-05-02 | $3.62M derived: sum of 2 quarters · filed 2025-03-31 | $3.57M derived: sum of 3 quarters · filed 2025-03-31 | $3.84M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $712.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $662.00K derived: sum of 2 quarters · filed 2025-03-31 | $935.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.03M 10-K · filed 2025-03-31 |
| 2022-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $223.00K derived: sum of 2 quarters · filed 2023-10-30 | $318.00K 10-Q · filed 2023-10-30 | $611.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $368.00K 10-Q · filed 2023-07-31 | $661.00K derived: sum of 3 quarters · filed 2024-03-28 | $2.70M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $95.00K 10-Q · filed 2023-05-02 | $388.00K derived: sum of 2 quarters · filed 2024-03-28 | $2.43M derived: sum of 3 quarters · filed 2024-03-28 | $3.20M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $293.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.33M derived: sum of 2 quarters · filed 2024-03-28 | $3.10M derived: sum of 3 quarters · filed 2024-03-28 | $3.17M 10-K · filed 2024-03-28 |
| 2021-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.81M derived: sum of 2 quarters · filed 2022-11-07 | $2.88M 10-Q · filed 2022-11-07 | $2.92M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $771.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $838.00K 10-Q · filed 2022-08-01 | $877.00K derived: sum of 3 quarters · filed 2023-03-28 | |
| 2021-03-31 | $67.00K 10-Q · filed 2022-05-16 | $106.00K derived: sum of 2 quarters · filed 2023-03-28 | ||
| 2020-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $51.00K 10-K · filed 2023-03-28 | ||
| 2020-09-30 | $12.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |